Russian Pharmaceutical sector, threat or opportunity ?

Healthcare Market Forecast Healthcare provision, in general, will remain poor in Russia. Significant disparities remain between the more populous and economically affluent West and the poorer and rural East. Moreover, a critical lack of funding will continue to hamper the provision of care. State expenditure will pick up as the economy gradually recovers from recession, [...]

By |2019-03-18T09:06:42+00:00March 18th, 2019|Healthcare|0 Comments

The developing moroccan healthcare sector will create opportunity In the regional Pharmaceutical Market

Disparities in healthcare access still persist. Almost 15 years after Morocco’s major healthcare reforms aimed at reducing health inequalities across the country, access to healthcare services for low-income and rural portions of the population remains challenging . Reportedly les s than half of the population have healthcare coverage across the country, while this proportion falls [...]

By |2019-03-05T08:01:09+00:00March 5th, 2019|Healthcare|0 Comments

Lilly’s Oncology Ambitions, Loxo Acquisition is a perfect portfolio match

Eli Lilly and Loxo Oncology have entered into a definitive agreement for Lilly to acquire Loxo Oncology for USD235.00 per share in cash, or approximately USD8.0bn.  We also noted, in 2018, that Lilly would undertake small to mid-size acquisitions, and this is likely the just the first of Lilly's 2019 deals, whilst expected to be the biggest. The transaction [...]

By |2019-01-16T12:38:54+00:00January 16th, 2019|Healthcare, Warfare Theory|0 Comments

Immuno-Oncology, the next’s Takeda strategic challenge

Takeda Pharmaceutical Company has announced new research collaborations in immuno-oncology (IO), an area of key strategic focus for the company. Through these collaborations, Takeda seeks to accelerate the discovery of next-generation cancer immunotherapies, including novel cell therapy approaches that may provide important opportunities for addressing the needs of patients with hard-to-treat cancers. Takeda is currently aiming [...]

By |2019-01-14T18:53:19+00:00January 14th, 2019|Healthcare|0 Comments

CAR-T cells, an industrial challenge for Novartis oncology

Novartis has offered to acquire CellforCure in order to expand its manufacturing capacity for innovative cell and gene therapies. The proposed acquisition builds on an existing partnership between the two firms which involves contract manufacturing of Novartis' CAR-T cell therapy Kymriah (tisagenlecleucel). Specific cost details have not yet been announced; however, Novartis has stated that it expects the deal to be [...]

By |2019-01-10T13:22:34+00:00January 10th, 2019|Healthcare|0 Comments

Pharmaceutical marketing ethical and responsible conduct, a real challenge for some pharmaceutical companies

Marketing of pharmaceutical products is of serious ethical concerns. Companies’ sales representatives should be ‘adequately trained and possess sufficient medical and technical knowledge to present information about the products in an accurate and responsible manner’. Sales representatives are not allowed to exaggerate the capabilities of the product. Marketing of pharmaceutical products may bring potential risks [...]

By |2019-01-08T08:58:04+00:00January 8th, 2019|Healthcare|0 Comments

Dengue Vaccine, a new race innovation

Merck & Co and Instituto Butantan have entered into a collaboration agreement to develop vaccines to protect against dengue virus disease. Instituto Butantan and Merck have licensed certain rights from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), for the development of live attenuated tetravalent vaccines (LATV). Instituto [...]

By |2019-01-02T09:37:10+00:00January 2nd, 2019|Healthcare|0 Comments

Biosimilar Drug Outlook 2019

As we anticipated in 2017, 2018 proved to be an exceptional year for biosimilars in the US. The FDA approved seven biosimilars during the year, more than any year before and almost doubling the total number of approved biosimilars to 15. This proved to be the second year in a row that the total number of [...]

By |2019-01-01T09:58:52+00:00January 1st, 2019|Healthcare|0 Comments

Next Generation Of Pneumococcal Vaccines In Development Race

Pfizer has advanced in the race for a new pneumococcal vaccine, having announced the initiation of a Phase III programme for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years and older. Protection from 20 pneumococcal sereotypes will [...]

By |2018-12-29T07:40:34+00:00December 29th, 2018|Healthcare|0 Comments